Nergiz DAĞOĞLU, Ethem N. ORAL, Seden KÜÇÜCÜK, Şule KARAMAN, Alptekin ARİFOĞLU

Definitive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Dose and Fractionation

Definitive radiotherapy plays a major role in the treatment of locallyadvanced non-small cell lung cancer (LA NSCLC). After theimpact of RT dose for lung cancer was established, a number of trialswere structured with the aim of better local control and overallsurvival by either dose escalation or shortening the total treatmenttime through conventional/altered fractionation, even in combinationwith chemotherapy (CT) and other targeted agents. In spite ofthe increased number of these studies, the optimal dose or fractionationstill remains to be determined. Another aspect questioned isthe incorporation of these higher doses and shorter treatment timeswith chemotherapy or targeted agents. This review summarises theresults of significant trials on dose and altered fractionation in thetreatment of LA-NSCLC with an emphasis on possible future perspectives.

PDF

___

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. Cancer J Clin 2012;62:10-29. [CrossRef]
2. Perez CA, Stanley K, Rubin P, Kramer S, Brady L, Perez-Tamayo R, et al. A prospective randomize study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Cancer 1980;45:2744-53. [CrossRef]
3. Martel MK, Ten Haken RK, Hazuka MB, Kessler ML, Strawderman M, Turrisi AT, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999;24: 31-7. [CrossRef]
4. Bradley J, Graham MV, Winter K. Toxicity and outcome results of RTOG 9311: A phase I-II dose escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318-28. [CrossRef]
5. Rosenzweig KE, Fox JL, Yorke E. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005;103: 2118-27. [CrossRef]
6. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205. [CrossRef]
7. Bradley JD, Moughan J, Graham MV, Byhardt R, Govindan R, Fowler J, et al. A Phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: Phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys 2010;77:367-72. [CrossRef]
8. Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIa/b nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-23. [CrossRef]
9. Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26:2457-63. [CrossRef]
10. Salama JK, Stinchcombe TE, Gu L et al. Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys 2011;81:269-274. [CrossRef]
11. Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locallyadvanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiation Oncology Biol Phys 2012; 82: 425-34. [CrossRef]
12. Bradley JD, Paulus R, Komaki R, Masters G, Forster K, Schild SE, et al. A randomized phase III comparison of standard-dose (60 Gy) versus highdose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage IIIa/IIIb non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617. Presented at: 53rd Annual Meeting of the American Society of Radiation Oncology. Miami, FL, USA, 2-6 October 2011.
13. Chang JY, De Ruysscher D. Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. J Thorac Dis 2014;6:285-6.
14. Kerr KM, Lamb D. Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. Br J Cancer 1984;50:343-9. [CrossRef]
15. Mauguen A1, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis. J Clin Oncol 2012;30:2788-97. [CrossRef]
16. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with >=69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-smallcell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543-55.
17. Sause W, Kolesar P, Taylor S IV, Johnson D, Livingston R, Komaki R, et al. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-64. [CrossRef]
18. Lee JS, Scott C, Komaki R et al. Concurrent chemo-radiotherapy with oral VP-16 and cisplatin for locally advanced inoperable non-small cell lung cancer: RTOG protocol 91-06. J Clin Oncol 1996;14:1055-64.
19. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13:452-8.
20. Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-60. [CrossRef]
21. Fournel P. RTOG 94-10: Keenly Awaited Results Validating the Best Therapeutic Strategy for Locally Advanced Non-Small Cell Lung Cancer. J Natl Cancer Inst 2011;103:1425-7. [CrossRef]
22. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-5. [CrossRef]
23. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999;52:137-48. [CrossRef]
24. Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011;100:76-85. [CrossRef]
25. Vokes EE. CHART for non-small-cell lung cancer-promises and limitations. Lancet 1997;350:156-7. [CrossRef]
26. Hatton M, Nankivell M, Lyn E, Falk S, Pugh C, Navani N, et al. Induction chemotherapy and continuous hyper-fractionated accelerated radiotherapy (CHART) for patients with locally advanced inoperable nonsmall cell lung cancer: the MRC INCH randomised trial. Int J Radiat Oncol Biol Phys 2011; 81: 712-8. [CrossRef]
27. Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIa and b non-small-cell lung cancer. J Clin Oncol 2005;23:3760-7. [CrossRef]
28. Oral EN, Bavbek S, Kizir A, Tenececi N, Yöney A, Kaytan E, et al. Preliminary analysis of a phase II study of Paclitaxel and continuous hyperfractionated accelerated radiotherapy in locally advanced nonsmall cell lung cancer. Lung Cancer 1999;25:191-8. [CrossRef]
29. Oral EN. Long term results of CHART and weekly Paclitaxel in locally advanced non-small cell lung cancer. Lung Cancer 2005;49:421-2. [CrossRef]
30. Pöttgen C, Eberhardt W, Bildat S, Stüben G, Stamatis G, Hillejan L, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high dose radiotehrapy for patients with locally advanced non small cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Ann Oncol 2002;13:403-11. [CrossRef]
31. Nyman J, Friesland S, Hallqvist A, Seke M, Bergström S, Thaning L, et al. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer 2009;65:62-7. [CrossRef]
32. Slawson RG, Salazar OM, Poussin-Rosillon H, Amin PP, Strohl R, Sewchand W. Once a week versus conventional daily radiation treatment for lung cancer: Final report. Int J Radiat Oncol Biol Phys 1988;15:61-8. [CrossRef]
33. Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:126-34. [CrossRef]
34. Bral S, Duchateau M, Versmessen H, Verdries D, Engels B, De Ridder M, et al. Toxicity report of a phase I-II dose escalation study in patients with inoperable, locally advanced non small-cell lung cancer with helical tomotherapy and concurrent chemotherapy. Cancer 2010;116: 241-50.